MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacadv.2026.103047

Медицинская библиотека · JACC. Advances · 2026

Determinants and Clinical Interpretation of Circulating Transthyretin in ATTR Amyloidosis.

Tsuruda Toshihiro, Suiko Yosuke, Matsuura Yunosuke, Komaki Soichi, Moribayashi Kohei, Tanaka Hiroki, Yamaguchi Masashi, Yamamoto Kinuko, Nakai Michikazu, Kaikita Koichi

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Transthyretin (TTR) amyloidosis (ATTR) ranges from localized to systemic disease, but the clinical interpretation of circulating TTR remains uncertain.

OBJECTIVES

The objective of the study was to characterize serum TTR in ATTR and identify longitudinal determinants, including disease-modifying therapies.

METHODS

In a single-center cohort, 134 patients with ATTR were enrolled. Serum TTR was measured at baseline (91 treatment-naive patients) and longitudinally during follow-up (347 measurements). Linear mixed-effects models were used to identify clinical and therapeutic determinants of circulating TTR.

RESULTS

Baseline TTR levels declined across clinical stages, from isolated carpal tunnel syndrome to symptomatic heart failure (27 vs 20 mg/dL). In longitudinal mixed-effects analyses, older age (β = -0.310, P < 0.001), inflammation (log10[C-reactive protein+0.1], β = -6.011, P < 0.001), and cardiac stress (log10BNP, β = -1.460, P = 0.033) were independently associated with lower TTR levels, whereas albumin was positively associated (β = 3.041; P < 0.001). Wild-type ATTR showed higher TTR levels than variant ATTR (β = 6.766; P < 0.001). Tetramer stabilizers increased TTR (β = 8.095; P < 0.001), whereas small-interfering RNA therapy reduced TTR levels (β = -13.456; P < 0.001). Following stabilizer initiation, median TTR increased from 21.5 mg/dL to 32.2 mg/dL after >730 days of therapy.

CONCLUSIONS

Circulating TTR reflects the integrated effects of systemic status and therapeutic interventions and should not be interpreted as a simple surrogate of ATTR disease severity.

Для цитирования: Tsuruda Toshihiro, Suiko Yosuke, Matsuura Yunosuke, Komaki Soichi, Moribayashi Kohei, Tanaka Hiroki, Yamaguchi Masashi, Yamamoto Kinuko, Nakai Michikazu, Kaikita Koichi. Determinants and Clinical Interpretation of Circulating Transthyretin in ATTR Amyloidosis.. JACC. Advances. 2026. DOI: 10.1016/j.jacadv.2026.103047.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.